title: Antibody response to measles and rubella vaccine by children with HIV infection.
abstract: To determine the immunogenicity of the measles and rubella components of the measles, mumps, and rubella virus (MMR) vaccine in human immunodeficiency virus (HIV)-infected children, we compared their response to that of uninfected controls. Sera were collected from HIV-infected patients and HIV seroreverters followed in our clinic and tested as close to 2 months post-MMR vaccination as possible. Specific IgG to both rubella and measles were measured by enzyme-linked immunosorbent assay. Of 20 children with HIV, 11 responded with adequate levels of antibody to measles. In the seroreverters, 12 of 13 responded. Of the measles responders, the median antibody level was significantly lower in the HIV-infected group than in the seroreverter group. In addition, HIV-infected responders tested at 9-15 months after vaccination demonstrated a significant decline in measles antibody levels. Although there was not a difference between the two cohorts in the proportion of patients who responded to the rubella component of the vaccine, there was a significant difference in the median antibody level of the responders of the two groups. We did not find a statistical difference in CD4 counts between responders and nonresponders. Alternate strategies will need to be established to prevent measles in HIV-infected children.
authors.affiliation: Department of Pediatrics, Maxwell Finland Laboratory for Infectious Diseases, Boston City Hospital/Boston University School of Medicine, Massachusetts.
authors.forename: A E
authors.initials: AE
authors.lastname: Breña
authors.forename: E R
authors.initials: ER
authors.lastname: Cooper
authors.forename: H J
authors.initials: HJ
authors.lastname: Cabral
authors.forename: S I
authors.initials: SI
authors.lastname: Pelton
mesh_terms: D000914:Antibodies, Viral / Q000096:biosynthesis*; D002675:Child, Preschool; D015331:Cohort Studies; D004338:Drug Combinations; D004797:Enzyme-Linked Immunosorbent Assay; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D007223:Infant; D008458:Measles Vaccine / Q000008:administration & dosage / Q000276:immunology*; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine / Q000008:administration & dosage; D012044:Regression Analysis; D012189:Retrospective Studies; D012411:Rubella Vaccine / Q000008:administration & dosage / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination
chemical_list: D000914:Antibodies, Viral; D004338:Drug Combinations; D007074:Immunoglobulin G; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine; C040901:rubella antibodies